glp 1 agonists and depression The risk of depression, anxiety, suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy π¨NEW BLOG ALERTπ¨ From regulating
Description
Kimura R, Okouchi M, Fujioka H, Ichiyanagi A, Ryuge F, Mizuno T, et al
Thus, spontaneous reporting may be the most effective method for identifying infrequent adverse events
Many patients who initially struggle with side effects tolerate the medication well after adjustments to their escalation schedule
conducted the Evaluating Liraglutide in Alzheimers Disease (ELAD) study to assess the effect of the novel GLP-1 analog liraglutide on AD, but they have not yet published their conclusions
